Scutellarin
CAS: 27740-01-8
Ref. TM-T2789
| 10mg | 49.00 € | ||
| 25mg | 83.00 € | ||
| 50mg | 130.00 € | ||
| 100mg | 168.00 € | ||
| 1mL*10mM (DMSO) | 55.00 € |
Estimated delivery in United States, on Tuesday 17 Dec 2024
Product Information
Name:
Scutellarin
Synonyms:
- Scutellarein-7-glucuronide
- Breviscapinun
- Breviscapine
- Breviscapin
- 5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl β-<span class="text-smallcaps">D</span>-glucopyranosiduronic acid
- 7-(beta-D-Glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
- Flavone, 4′,5,6,7-tetrahydroxy-, 7-β-<span class="text-smallcaps">D</span>-glucopyranuronoside
- Glucopyranosiduronic acid, 5,6-dihydroxy-2-(p-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, β-<span class="text-smallcaps">D</span>-
- Scutellarein 7-O-β-<span class="text-smallcaps">D</span>-glucuronide
- Scutellarein 7-O-β-glucuronide
- See more synonyms
- Scutellarein 7-glucuronide
- Scutellarein 7-β-<span class="text-smallcaps">D</span>-glucuronide
- Scutellarein 7-β-<span class="text-smallcaps">D</span>-glucuronoside
- Scutellarin B
- β-<span class="text-smallcaps">D</span>-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl
Description:
Scutellarin from Scutellaria inhibits RANKL in osteoclasts and STAT3/Girdin/Akt in HCC cells.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
462.36
Formula:
C21H18O12
Purity:
95.86% - 99.32%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T2789 Scutellarin
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
